Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie logo

News provided by

AbbVie

Oct 30, 2024, 07:38 ET

Share this article

Share toX

Share this article

Share toX

  • Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense
     
  • Delivers Third-Quarter Net Revenues of $14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis
     
  • Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Percent on a Reported Basis, or 4.8 Percent on an Operational Basis; Global Humira Net Revenues Were $2.227 Billion; Global Skyrizi Net Revenues Were $3.205 Billion; Global Rinvoq Net Revenues Were $1.614 Billion
     
  • Third-Quarter Global Net Revenues from the Oncology Portfolio Were $1.687 Billion, an Increase of 11.6 Percent on a Reported Basis, or 13.0 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $828 Million; Global Venclexta Net Revenues Were $677 Million
     
  • Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.363 Billion, an Increase of 15.6 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $848 Million; Global Vraylar Net Revenues Were $875 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $445 Million
     
  • Third-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.239 Billion, a Decrease of 0.1 Percent on a Reported Basis, or an Increase of 1.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $671 Million; Global Juvederm Net Revenues Were $258 Million
     
  • Successfully Completed Acquisition of Cerevel, Adding Pipeline of Highly Complementary Assets to AbbVie's Existing Neuroscience Portfolio
     
  • Raises 2024 Adjusted Diluted EPS Guidance Range from $10.67 - $10.87 to $10.90 - $10.94, which Includes an Unfavorable Impact of $0.64 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2024
     
  • Announces 2025 Dividend Increase of 5.8 Percent, Beginning with Dividend Payable in February 2025

NORTH CHICAGO, Ill., Oct. 30, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2024.

"We delivered another quarter of strong commercial execution and significant pipeline progress," said Robert A. Michael, chief executive officer, AbbVie. "Based upon the momentum of AbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend."

Third-Quarter Results

  • Worldwide net revenues were $14.460 billion, an increase of 3.8 percent on a reported basis, or 4.9 percent on an operational basis.
     
  • Global net revenues from the immunology portfolio were $7.046 billion, an increase of 3.9 percent on a reported basis, or 4.8 percent on an operational basis.
    • Global Humira net revenues of $2.227 billion decreased 37.2 percent on a reported basis, or 36.5 percent on an operational basis. U.S. Humira net revenues were $1.765 billion, a decrease of 41.6 percent. Internationally, Humira net revenues were $462 million, a decrease of 12.4 percent on a reported basis, or 7.8 percent on an operational basis.
    • Global Skyrizi net revenues were $3.205 billion, an increase of 50.8 percent on a reported basis, or 51.5 percent on an operational basis.
    • Global Rinvoq net revenues were $1.614 billion, an increase of 45.3 percent on a reported basis, or 47.4 percent on an operational basis.
       
  • Global net revenues from the oncology portfolio were $1.687 billion, an increase of 11.6 percent on a reported basis, or 13.0 percent on an operational basis.
    • Global Imbruvica net revenues were $828 million, a decrease of 8.8 percent, with U.S. net revenues of $618 million and international profit sharing of $210 million.
    • Global Venclexta net revenues were $677 million, an increase of 14.8 percent on a reported basis, or 18.2 percent on an operational basis.
    • Global Elahere net revenues were $139 million.
       
  • Global net revenues from the neuroscience portfolio were $2.363 billion, an increase of 15.6 percent on a reported basis, or 16.0 percent on an operational basis.
    • Global Botox Therapeutic net revenues were $848 million, an increase of 13.4 percent on a reported basis, or 14.4 percent on an operational basis.
    • Global Vraylar net revenues were $875 million, an increase of 16.6 percent.
    • Global Ubrelvy net revenues were $269 million, an increase of 15.3 percent.
    • Global Qulipta net revenues were $176 million, an increase of 33.6 percent.
       
  • Global net revenues from the aesthetics portfolio were $1.239 billion, a decrease of 0.1 percent on a reported basis, or an increase of 1.8 percent on an operational basis.
    • Global Botox Cosmetic net revenues were $671 million, an increase of 8.2 percent on a reported basis, or 9.9 percent on an operational basis.
    • Global Juvederm net revenues were $258 million, a decrease of 19.7 percent on a reported basis, or 16.9 percent on an operational basis.
       
  • On a GAAP basis, the gross margin ratio in the third quarter was 70.9 percent. The adjusted gross margin ratio was 84.4 percent.
     
  • On a GAAP basis, selling, general and administrative (SG&A) expense was 29.1 percent of net revenues. The adjusted SG&A expense was 23.0 percent of net revenues.
     
  • On a GAAP basis, research and development (R&D) expense was 14.7 percent of net revenues. The adjusted R&D expense was 14.2 percent of net revenues.
     
  • Acquired IPR&D and milestones expense was 0.6 percent of net revenues.
     
  • On a GAAP basis, the operating margin in the third quarter was 26.5 percent. The adjusted operating margin was 46.7 percent.
     
  • Net interest expense was $591 million.
     
  • On a GAAP basis, the tax rate in the quarter was 25.0 percent. The adjusted tax rate was 16.2 percent.
     
  • Diluted EPS in the third quarter was $0.88 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.00. These results include an unfavorable impact of $0.04 per share related to acquired IPR&D and milestones expense.

Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. 

Recent Events

  • AbbVie announced that it completed its acquisition of Cerevel, adding a pipeline of highly complementary assets to AbbVie's existing neuroscience portfolio. Cerevel's pipeline includes emraclidine, a potential best-in-class, next-generation antipsychotic, that is being studied for the treatment of schizophrenia; tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease (PD); as well as CVL-354, a potential best-in-class kappa opioid receptor (KOR) antagonist being studied for the treatment of major depressive disorder (MDD). Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade.
         
  • AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-1 trial evaluating tavapadon as a fixed-dose monotherapy treatment in early PD. In the study, tavapadon met the primary endpoint, demonstrating a statistically significant improvement from baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26. Tavapadon also met the key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score. Full results from the TEMPO-1 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for PD. Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
     
  • AbbVie announced the U.S. Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) as the first subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced PD. The approval was supported by results from a pivotal Phase 3 head-to-head, randomized and controlled clinical trial that demonstrated a statistically significant improvement in "on" time without troublesome dyskinesia and decreased "off" time, compared to oral immediate-release carbidopa/levodopa (CD/LD).
     
  • AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer's disease (AD). The acquisition also allows AbbVie to utilize Aliada's novel BBB-crossing technology to enhance discovery and development efforts across neuroscience.
     
  • AbbVie and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboration expands upon the success of nearly two decades of partnership on CNS projects.
     
  • AbbVie announced the European Commission (EC) approved Skyrizi (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to conventional or biologic therapy. The approval was supported by data from two pivotal Phase 3 trials in which Skyrizi achieved the primary endpoint of clinical remission as well as key secondary endpoints. This marketing authorization for Skyrizi marks its fourth approved indication in the European Union (EU). Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
     
  • At the European Academy of Dermatology and Venerology (EADV) Congress 2024, AbbVie shared more than 30 presentations that showcased the depth and strength of AbbVie's dermatology portfolio. Presentations highlighted data for Rinvoq (upadacitinib), Skyrizi and lutikizumab across a multitude of dermatological conditions.
     
  • AbbVie announced that the EC granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of prior therapy. Tepkinly is the first subcutaneous bispecific antibody conditionally approved as a monotherapy in the EU to treat both r/r FL and r/r diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy. The EC approval is supported by data from the Phase 1/2 EPCORE NHL-1 clinical trial, which evaluated the safety and efficacy of Tepkinly in adult patients with r/r FL. Tepkinly is being co-developed by AbbVie and Genmab.
     
  • AbbVie announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior treatment regimens. The CHMP's opinion is supported by results of the Phase 3 MIRASOL clinical trial and the EC decision on this indication for Elahere is anticipated later this year.
     
  • AbbVie announced submission of a Biologics License Application (BLA) to the FDA for accelerated approval (AA) of Teliso-V (telisotuzumab vedotin) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. The BLA is supported by data from the Phase 2 LUMINOSITY clinical trial and review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program. There are currently no approved anti-cancer therapies specifically for c-Met overexpressing NSCLC and if approved, Teliso-V would be the first-in-class therapy for this patient population.
     
  • At the European Society for Medical Oncology (ESMO) Congress 2024, AbbVie showcased new data from its innovative antibody-drug conjugate (ADC) platform in tumor types with high unmet needs. Highlights included full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating Elahere for high FRα expressing platinum-sensitive ovarian cancer (PSOC); patient reported outcomes from the Phase 2 LUMINOSITY trial, evaluating Teliso-V in advanced NSCLC; as well as new safety and efficacy data in pre-treated patients with advanced NSCLC and gastroesophageal (GEA) cancer, from a Phase 1 study of ABBV-400 (telisotuzumab adizutecan).
     
  • Allergan Aesthetics announced the FDA approved Botox Cosmetic (onabotulinumtoxinA) for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults. Botox Cosmetic is the first product with four aesthetic indication areas: forehead lines, frown lines, crow's feet lines, and now platysma bands, making it the first product of its kind to go beyond the face.
     
  • Allergan Aesthetics announced the launch of Botox Cosmetic for the treatment of masseter muscle prominence (MMP) in China. The approval is supported by Botox Cosmetic's well-established safety profile as well as clinical trial data that demonstrated Botox Cosmetic is effective in reducing the prominence of the masseter muscle. Botox Cosmetic is the first neurotoxin approved in China for MMP, the largest global MMP market. Allergan Aesthetics intends to develop Botox Cosmetic treatment for MMP in additional global markets and expand the use of Botox Cosmetic in the lower face.
     
  • At the American Society for Dermal Surgery (ASDS), Allergan Aesthetics presented a total of 12 abstracts that showcased its commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments. Highlights included four Best of Cosmetic Abstracts as well as a panel discussion on the impact of social media on patient experience and expectations when considering aesthetic treatment.

Full-Year 2024 Outlook

AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted. Any potential IPR&D and milestones expense related to the recently announced acquisition of Aliada Therapeutics is also excluded from AbbVie's 2024 adjusted diluted EPS guidance, as the transaction is expected to close in the fourth quarter of 2024.

Company Declares Dividend Increase of 5.8 Percent

AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.55 per share to $1.64 per share beginning with the dividend payable on February 14, 2025 to shareholders of record as of January 15, 2025. This reflects an increase of approximately 5.8 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn.

Conference Call

AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our third-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.

Non-GAAP Financial Results

Financial results for 2024 and 2023 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

AbbVie Inc.

Key Product Revenues

Quarter Ended September 30, 2024

(Unaudited)









% Change vs. 3Q23


Net Revenues (in millions)


Reported


Operationala


U.S.


Int'l.


Total


U.S.


Int'l.


Total


Int'l.


Total

NET REVENUES

$11,148


$3,312


$14,460


2.7 %


7.7 %


3.8 %


12.4 %


4.9 %

















Immunology

5,713


1,333


7,046


0.3


22.7


3.9


28.4


4.8

Humira

1,765


462


2,227


(41.6)


(12.4)


(37.2)


(7.8)


(36.5)

Skyrizi

2,778


427


3,205


48.3


70.0


50.8


75.7


51.5

Rinvoq

1,170


444


1,614


45.9


44.0


45.3


51.6


47.4

















Oncology

1,113


574


1,687


14.4


6.5


11.6


10.3


13.0

Imbruvicab

618


210


828


(8.9)


(8.4)


(8.8)


(8.4)


(8.8)

Venclexta

340


337


677


21.5


8.9


14.8


15.4


18.2

Elahere

139


—


139


n/m


n/m


n/m


n/m


n/m

Epkinlyc

16


27


43


13.4


>100.0


>100.0


>100.0


>100.0

















Aesthetics

791


448


1,239


3.9


(6.4)


(0.1)


(1.6)


1.8

Botox Cosmetic

414


257


671


6.5


10.9


8.2


15.5


9.9

Juvederm Collection

105


153


258


(10.2)


(25.1)


(19.7)


(20.8)


(16.9)

Other Aesthetics

272


38


310


6.4


(10.0)


4.0


(2.0)


5.1

















Neuroscience

2,088


275


2,363


14.9


21.2


15.6


25.1


16.0

Botox Therapeutic

708


140


848


13.1


14.6


13.4


20.7


14.4

Vraylar

873


2


875


16.5


49.3


16.6


51.9


16.6

Duodopa

24


87


111


(4.7)


(7.1)


(6.6)


(6.4)


(6.0)

Ubrelvy

261


8


269


13.6


>100.0


15.3


>100.0


15.3

Qulipta

168


8


176


28.3


>100.0


33.6


>100.0


33.6

Other Neuroscience

54


30


84


(4.1)


>100.0


36.4


>100.0


37.1

















Eye Care

240


285


525


(22.9)


(3.5)


(13.5)


1.2


(11.2)

Ozurdex

33


86


119


(2.3)


(0.3)


(0.9)


2.5


1.1

Lumigan/Ganfort

58


58


116


>100.0


(7.0)


27.2


(2.7)


30.2

Alphagan/Combigan

26


36


62


(15.3)


(10.0)


(12.3)


(4.5)


(9.2)

Restasis

8


13


21


(92.5)


2.1


(82.2)


8.1


(81.5)

Other Eye Care

115


92


207


1.7


(2.0)


—


4.2


2.8

















Other Key Products

710


164


874


(5.6)


(22.1)


(9.3)


(19.5)


(8.7)

Mavyret

147


155


302


(12.7)


(23.1)


(18.4)


(20.5)


(17.0)

Creon

338


—


338


10.6


n/m


10.6


n/m


10.6

Linzess/Constella

225


9


234


(19.2)


0.4


(18.6)


2.0


(18.6)



a

"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

b

Reflects profit sharing for Imbruvica international revenues.

c

Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.

n/m = not meaningful

AbbVie Inc.

Key Product Revenues

Nine Months Ended September 30, 2024

(Unaudited)









% Change vs. 9M23


Net Revenues (in millions)


Reported


Operationala


U.S.


Int'l.


Total


U.S.


Int'l.


Total


Int'l.


Total

NET REVENUES

$31,295


$9,937


$41,232


1.7 %


7.5 %


3.0 %


12.2 %


4.1 %

















Immunology

15,582


3,806


19,388


(2.4)


18.2


1.1


24.2


2.1

Humira

5,896


1,415


7,311


(37.4)


(15.8)


(34.1)


(10.8)


(33.3)

Skyrizi

6,774


1,166


7,940


45.8


61.8


47.9


66.6


48.5

Rinvoq

2,912


1,225


4,137


53.6


49.6


52.4


58.5


55.1

















Oncology

3,117


1,747


4,864


11.1


9.2


10.4


12.7


11.7

Imbruvicab

1,823


676


2,499


(8.0)


(4.9)


(7.2)


(4.9)


(7.2)

Venclexta

921


1,007


1,928


13.6


13.4


13.5


19.7


16.8

Elaherec

331


—


331


n/m


n/m


n/m


n/m


n/m

Epkinlyd

42


64


106


>100.0


>100.0


>100.0


>100.0


>100.0

















Aesthetics

2,430


1,448


3,878


2.7


(7.0)


(1.2)


(2.2)


0.7

Botox Cosmetic

1,253


780


2,033


2.9


4.5


3.5


9.1


5.3

Juvederm Collection

349


549


898


(4.1)


(19.3)


(14.0)


(14.6)


(10.9)

Other Aesthetics

828


119


947


5.6


(8.7)


3.5


(1.8)


4.5

















Neuroscience

5,697


793


6,490


15.6


14.1


15.4


17.0


15.8

Botox Therapeutic

1,988


422


2,410


8.8


8.6


8.8


13.1


9.6

Vraylar

2,338


5


2,343


18.9


76.0


18.9


76.9


18.9

Duodopa

72


267


339


(3.3)


(4.4)


(4.1)


(4.0)


(3.8)

Ubrelvy

685


18


703


19.3


>100.0


20.9


>100.0


20.9

Qulipta

442


15


457


51.3


>100.0


55.5


>100.0


55.5

Other Neuroscience

172


66


238


(11.6)


>100.0


13.5


>100.0


14.1

















Eye Care

706


890


1,596


(24.7)


(0.3)


(12.8)


3.8


(10.8)

Ozurdex

102


272


374


(4.4)


10.0


5.7


13.1


7.8

Lumigan/Ganfort

129


181


310


(9.5)


(8.7)


(9.0)


(5.9)


(7.4)

Alphagan/Combigan

54


116


170


(40.3)


(0.1)


(17.7)


6.9


(13.8)

Restasis

70


40


110


(73.4)


(7.4)


(64.2)


(2.2)


(63.5)

Other Eye Care

351


281


632


5.3


(2.4)


1.7


2.1


3.8

















Other Key Products

2,146


590


2,736


(3.4)


(4.2)


(3.6)


(0.9)


(2.9)

Mavyret

458


562


1,020


(13.9)


(4.6)


(9.0)


(1.2)


(7.2)

Creon

995


—


995


11.5


n/m


11.5


n/m


11.5

Linzess/Constella

693


28


721


(13.2)


6.2


(12.6)


6.0


(12.6)



a 

"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

b 

Reflects profit sharing for Imbruvica international revenues.

c 

Reflects partial year Elahere revenue based on the February 12, 2024 close date of the ImmunoGen acquisition.

d 

Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.

n/m = not meaningful

AbbVie Inc.

Consolidated Statements of Earnings

(Unaudited)


(in millions, except per share data)

Third Quarter

Ended September 30


Nine Months

Ended September 30


2024


2023


2024


2023

Net revenues

$       14,460


$       13,927


$       41,232


$        40,017

Cost of products sold

4,212


6,485


12,508


14,711

Selling, general and administrative

4,205


3,372


10,897


9,679

Research and development

2,130


1,723


6,017


5,748

Acquired IPR&D and milestones

82


66


1,183


496

Other operating income

—


—


—


(179)

Total operating costs and expenses

10,629


11,646


30,605


30,455









Operating earnings

3,831


2,281


10,627


9,562









Interest expense, net

591


398


1,550


1,306

Net foreign exchange loss (gain)

(3)


25


2


97

Other expense (income), net

1,159


(95)


3,090


3,121

Earnings before income tax expense

2,084


1,953


5,985


5,038

Income tax expense

520


172


1,676


989

Net earnings

1,564


1,781


4,309


4,049

Net earnings attributable to noncontrolling interest

3


3


9


8

Net earnings attributable to AbbVie Inc.

$          1,561


$          1,778


$          4,300


$          4,041









Diluted earnings per share attributable to AbbVie Inc.

$            0.88


$            1.00


$            2.41


$            2.26









Adjusted diluted earnings per sharea

$            3.00


$            2.95


$            7.96


$            8.32









Weighted-average diluted shares outstanding

1,772


1,771


1,772


1,772



a

Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)


1.     Specified items impacted results as follows:



Quarter Ended September 30, 2024

(in millions, except per share data)

Earnings


Diluted


Pre-tax


After-taxa


EPS

As reported (GAAP)

$              2,084


$              1,561


$                0.88

Adjusted for specified items:






Intangible asset amortization

1,888


1,600


0.89

Acquisition and integration costs

307


283


0.16

Change in fair value of contingent consideration                             

1,356


1,321


0.75

Litigation matters

692


543


0.31

Other

30


19


0.01

As adjusted (non-GAAP)

$              6,357


$              5,327


$                3.00


a     Represents net earnings attributable to AbbVie Inc.


Acquisition and integration costs primarily reflect costs related to the Cerevel Therapeutics acquisition. Litigation matters
primarily include charges related to actual and potential settlements of litigation.


Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2024 included
acquired IPR&D and milestone expense of $82 million on a pre-tax and $74 million on an after-tax basis, representing
an unfavorable impact of $0.04 to both diluted EPS and adjusted diluted EPS.


2.     The impact of the specified items by line item was as follows:



Quarter Ended September 30, 2024

(in millions)

Cost of
products
sold


SG&A


R&D


Other
expense
(income),
net

As reported (GAAP)

$      4,212


$      4,205


$      2,130


$      1,159

Adjusted for specified items:








Intangible asset amortization

(1,888)


—


—


—

Acquisition and integration costs

(43)


(189)


(75)


—

Change in fair value of contingent consideration                       

—


—


—


(1,356)

Litigation matters

—


(692)


—


—

Other

(30)


2


—


(2)

As adjusted (non-GAAP)

$      2,251


$      3,326


$      2,055


$       (199)


3.     The adjusted tax rate for the third quarter of 2024 was 16.2 percent, as detailed below:



Quarter Ended September 30, 2024

(dollars in millions)

Pre-tax
earnings


Income taxes


Tax rate

As reported (GAAP)

$              2,084


$                 520


25.0 %

Specified items

4,273


507


11.9 %

As adjusted (non-GAAP)                                                               

$              6,357


$              1,027


16.2 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)


1.     Specified items impacted results as follows:



Quarter Ended September 30, 2023

(in millions, except per share data)

Earnings


Diluted


Pre-tax


After-taxa


EPS

As reported (GAAP)

$              1,953


$              1,778


$                1.00

Adjusted for specified items:






Intangible asset amortization

2,039


1,728


0.98

Intangible asset impairment

2,114


1,660


0.93

Acquisition and integration costs

60


54


0.03

Change in fair value of contingent consideration                            

8


8


—

Other

59


22


0.01

As adjusted (non-GAAP)

$              6,233


$              5,250


$                2.95


a     Represents net earnings attributable to AbbVie Inc.


Intangible asset impairment reflects a partial impairment charge related to the U.S. Imbruvica intangible asset acquired as
part of the 2015 acquisition of Pharmacyclics, Inc. The intangible asset impairment charge was triggered by selection of
Imbruvica for price negotiation as part of the IRA of 2022, which contributed to a significant decrease in the estimated future
cash flows for the product


Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2023 included
acquired IPR&D and milestones expense of $66 million on a pre-tax and after-tax basis, representing an unfavorable
impact of $0.04 to both diluted EPS and adjusted diluted EPS.


2.     The impact of the specified items by line item was as follows: 



Quarter Ended September 30, 2023

(in millions)

Cost of
products
sold


SG&A


R&D


Other
expense
(income),
net

As reported (GAAP)

$     6,485


$     3,372


$     1,723


$        (95)

Adjusted for specified items:








Intangible asset amortization

(2,039)


—


—


—

Intangible asset impairment

(2,114)


—


—


—

Acquisition and integration costs

(18)


(40)


(2)


—

Change in fair value of contingent consideration                            

—


—


—


(8)

Other

(13)


(2)


(1)


(43)

As adjusted (non-GAAP)

$     2,301


$     3,330


$     1,720


$      (146)


 3.     The adjusted tax rate for the third quarter of 2023 was 15.7 percent, as detailed below:



Quarter Ended September 30, 2023

(dollars in millions)

Pre-tax
earnings


Income taxes


Tax rate

As reported (GAAP)

$              1,953


$                 172


8.8 %

Specified items

4,280


808


18.9 %

As adjusted (non-GAAP)                                                              

$              6,233


$                 980


15.7 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)


1.     Specified items impacted results as follows:



Nine Months Ended September 30, 2024

(in millions, except per share data)

Earnings


Diluted


Pre-tax


After-taxa


EPS

As reported (GAAP)

$              5,985


$              4,300


$                2.41

Adjusted for specified items:






Intangible asset amortization

5,726


4,854


2.73

Acquisition and integration costs

963


894


0.50

Change in fair value of contingent consideration                             

3,492


3,402


1.92

Litigation matters

737


585


0.33

Other

96


122


0.07

As adjusted (non-GAAP)

$           16,999


$           14,157


$                7.96


a     Represents net earnings attributable to AbbVie Inc.


Acquisition and integration costs primarily reflect costs related to the ImmunoGen and Cerevel Therapeutics acquisitions.
Litigation matters primarily include charges related to actual and potential settlements of litigation.


Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2024 included acquired
IPR&D and milestones expense of $1.2 billion on a pre-tax and $1.1 billion on an after-tax basis, representing an unfavorable
impact of $0.64 to both diluted EPS and adjusted diluted EPS.


2.     The impact of the specified items by line item was as follows: 



Nine Months Ended September 30, 2024

(in millions)

Cost of
products
sold


SG&A


R&D


Interest
expense,
net


Other
expense
(income),
net

As reported (GAAP)

$    12,508


$    10,897


$      6,017


$      1,550


$      3,090

Adjusted for specified items:










Intangible asset amortization

(5,726)


—


—


—


—

Acquisition and integration costs

(201)


(504)


(234)


(24)


—

Change in fair value of contingent consideration

—


—


—


—


(3,492)

Litigation matters

—


(737)


—


—


—

Other

(87)


17


—


—


(26)

As adjusted (non-GAAP)

$      6,494


$      9,673


$      5,783


$      1,526


$        (428)


3.     The adjusted tax rate for the first nine months of 2024 was 16.7 percent, as detailed below:



Nine Months Ended September 30, 2024

(dollars in millions)

Pre-tax
earnings


Income taxes


Tax rate

As reported (GAAP)

$             5,985


$              1,676


28.0 %

Specified items

11,014


1,157


10.5 %

As adjusted (non-GAAP)                                                                

$           16,999


$              2,833


16.7 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)


1.     Specified items impacted results as follows:



Nine Months Ended September 30, 2023

(in millions, except per share data)

Earnings


Diluted


Pre-tax


After-taxa


EPS

As reported (GAAP)

$              5,038


$              4,041


$                2.26

Adjusted for specified items:






Intangible asset amortization

6,057


5,101


2.87

Intangible asset impairment

2,824


2,289


1.29

Acquisition and integration costs

38


15


0.01

Change in fair value of contingent consideration                             

3,432


3,348


1.88

Other

75


16


0.01

As adjusted (non-GAAP)

$           17,464


$           14,810


$                8.32


 a    Represents net earnings attributable to AbbVie Inc.


Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain
of $169 million related to the termination of a development liability associated with a previously divested product.  Intangible
asset impairment primarily reflects a partial impairment charge of $2.1 billion related to the U.S. Imbruvica intangible asset
acquired as part of the 2015 acquisition of Pharmacyclics, Inc. The intangible asset impairment was triggered by selection of
Imbruvica for price negotiation as part of the IRA of 2022, which contributed to a significant decrease in the estimated future
cash flows for the product.


Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2023 included acquired
IPR&D and milestones expense of $496 million on a pre-tax and $477 million on an after-tax basis, representing an unfavorable
impact of $0.27 to both diluted EPS and adjusted diluted EPS.


2.     The impact of the specified items by line item was as follows: 



Nine Months Ended September 30, 2023

(in millions)

Cost of
products
sold


SG&A


R&D


Other
operating
income


Other
expense
(income),
net

As reported (GAAP)

$  14,711


$     9,679


$     5,748


$      (179)


$     3,121

Adjusted for specified items:










Intangible asset amortization

(6,057)


—


—


—


—

Intangible asset impairment

(2,194)


—


(630)


—


—

Acquisition and integration costs

(66)


(134)


(7)


169


—

Change in fair value of contingent consideration     

—


—


—


—


(3,432)

Other

(45)


(13)


(4)


10


(23)

As adjusted (non-GAAP)

$     6,349


$     9,532


$     5,107


$           —


$      (334)


3.     The adjusted tax rate for the first nine months of 2023 was 15.2 percent, as detailed below:                                         



Nine Months Ended September 30, 2023

(dollars in millions)                                                                            

Pre-tax
earnings


Income taxes


Tax rate

As reported (GAAP)

$             5,038


$                 989


19.6 %

Specified items

12,426


1,657


13.3 %

As adjusted (non-GAAP)

$           17,464


$              2,646


15.2 %

SOURCE AbbVie

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA...

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Earnings

Earnings

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.